Hua Medicine’s Pivotal Phase III Monotherapy Trial of Dorzagliatin, a Dual-Acting Glucokinase Modulator, Achieves Primary Efficacy Endpoint in Patients with Type 2 Diabetes
November 11, 2019 11:00 ET
|
Hua Medicine
Phase III Monotherapy Trial (HMM0301) of Dorzagliatin Achieves Primary Efficacy Endpoint with 24-Week Topline ResultsFirst Phase III trial of a therapy targeting the underlying cause of type 2...
华领医药将于11月12日发布Dorzagliatin单药治疗III期临床试验24周顶线数据（HMM0301）
November 08, 2019 06:03 ET
|
Hua Medicine
上海, Nov. 08, 2019 (GLOBE NEWSWIRE) -- 华领医药（香港主板股票代码：2552）是一家专注于研发治疗全球2型糖尿病原创口服新药的生物技术公司，总部位于上海。今天华领医药宣布，dorzagliatin单药治疗临床试验(HMM0301)的24周顶线数据将于2019年11月12日公布，管理层将通过电话会议陈述该试验结果并回答各种问题。 日期:2019 年 11...
華領醫藥將於11月12日發佈Dorzagliatin單藥治療III期臨床試驗24周頂線資料（HMM0301）
November 08, 2019 06:03 ET
|
Hua Medicine
上海, Nov. 08, 2019 (GLOBE NEWSWIRE) -- 華領醫藥（香港主機板股票代碼：2552）是一家專注於研發治療全球2型糖尿病原創口服新藥的生物技術公司，總部位於上海。今天華領醫藥宣佈，dorzagliatin單藥治療臨床試驗(HMM0301)的24周頂線資料將於2019年11月12日公佈，管理層將通過電話會議陳述該試驗結果並回答各種問題。 日期:2019 年...
Hua Medicine to Release Phase III 24-Weeks Topline Data of Dorzagliatin Monotherapy Trial (HMM0301) on November 12
November 08, 2019 06:03 ET
|
Hua Medicine
SHANGHAI, China, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Hua Medicine (HKEX: 2552), a Shanghai-based drug development company focused on developing a global first-in-class oral drug for the treatment of...
华领医药公布最新研发管线
June 04, 2019 23:30 ET
|
Hua Medicine
TrialProductsExploratoryNDA EnablingDescription / Indication HMM0301Dorzagliatin (HMS5552) Phase III ongoingDrug-naïve T2D HMM0302Dorzagliatin + Metformin Phase III ongoingMetformin tolerant...
華領醫藥公佈最新研發管線
June 04, 2019 23:30 ET
|
Hua Medicine
TrialProductsExploratoryNDA EnablingDescription / Indication HMM0301Dorzagliatin (HMS5552) Phase III ongoingDrug-naïve T2D HMM0302Dorzagliatin + Metformin Phase III ongoingMetformin tolerant...
Hua Medicine – Business & Pipeline Update
June 04, 2019 23:30 ET
|
Hua Medicine
TrialProductsExploratoryNDA EnablingDescription / Indication HMM0301Dorzagliatin (HMS5552) Phase III ongoingDrug-naïve T2D HMM0302Dorzagliatin + Metformin Phase III ongoingMetformin tolerant...
華領醫藥於美國開展首項Dorzagliatin與SGLT-2抑制劑聯合用藥的研究
April 22, 2019 22:00 ET
|
Hua Medicine
上海, April 23, 2019 (GLOBE NEWSWIRE) --...
华领医药于美国开展首项Dorzagliatin与SGLT-2抑制剂联合用药的研究
April 22, 2019 22:00 ET
|
Hua Medicine
上海, April 23, 2019 (GLOBE NEWSWIRE) --...
Hua Medicine Initiates First Combination Study of Dorzagliatin with SGLT-2 in the United States
April 22, 2019 22:00 ET
|
Hua Medicine
SHANGHAI, China, April 22, 2019 (GLOBE NEWSWIRE) -- Hua Medicine (HKEX: 2552), a Shanghai-based drug development company focused on developing a global first-in-class oral drug for the treatment of...